FDA & Industry Veteran Brian E. Harvey, MD, PhD, Joins Thetis Pharmaceuticals as Senior Medical Director

Former FDA GI Division Director and V.P. of U.S. Regulatory Strategy at Pfizer to Guide Clinical and Regulatory Development of Thetis IBD Programs BRANFORD, CT – (GlobeNewswire – May 7, 2018) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing first-in-class, immuno-resolving small molecule drugs to treat inflammatory bowel disease (IBD), announced today that Brian […]

Thetis Builds SAB to Guide Development of Immuno-Resolving Therapies for IBD

Stephen Hanauer, MD, Joshua Korzenik, MD, and Florian Rieder, MD join the board BRANFORD, CT – (GlobeNewswire – December 11, 2017) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing oral, “immuno-resolving” therapies to treat inflammatory bowel disease (IBD), announced that Stephen Hanauer, MD, Josh Korzenik, MD, and Florian Rieder, MD, have joined Thetis’ Scientific […]

Senator Murphy Names Thetis Connecticut Innovator of the Month

WASHINGTON – In recognition of Crohn’s and Colitis Awareness Week, U.S. Senator Chris Murphy (D-Conn.) announced on Tuesday that Branford’s Thetis Pharmaceuticals – a biopharmaceutical company developing new oral therapies to treat inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis – is this month’s “Murphy’s Innovator of the Month.” Thetis has a proprietary HEALER™ […]

Thetis Receives $2.3 Million NIH Grant to Develop Immuno-Resolving Therapy for IBD

  Resolvin-based agent targets inflammation resolution and tissue regeneration without immunosuppression BRANFORD, CT – (GlobeNewswire – November 16, 2017) – Thetis Pharmaceuticals, a biopharmaceutical company developing “immuno-resolving” therapies for treatment of inflammatory bowel disease (IBD), today announced the receipt of a Fast-Track Small Business Innovation Research (SBIR) Grant from the National Institutes of Health (NIH). […]

Thetis Announces Pre-Clinical Data on TP-252

Preclinical data shows equivalence of TP-252 and EPA-FFA in modulating inflammatory eicosanoid profiles within the colon EPA-FFA has demonstrated clinical efficacy in reducing the rate of relapse in ulcerative colitis BRANFORD, CT May 8, 2017 – Thetis Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs for inflammatory bowel disease (IBD), today announced pre-clinical data […]